Clinical Trial Update: Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of SKB264 and Anlotinib for EGFR-TKI-resistant advanced non-small cell lung cancer with liver metastasis; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• SKB264

Snippet

Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Conditions: Non-small Cell Lung Cancer, EGFR Mutant Advanced Non-small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING